Insight Molecular Diagnostics (IMDX) Enterprise Value (2015 - 2026)

Insight Molecular Diagnostics has disclosed Enterprise Value across 12 years of filings, most recently posting -$28.9 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$28.9 million, up 6.68% year-over-year; the trailing twelve-month figure through Mar 2026 was -$28.9 million (up 6.68% YoY), and the FY2025 annual result was -$12.3 million, down 42.57% from the prior year.
• Enterprise Value came in at -$28.9 million for Q1 2026 at Insight Molecular Diagnostics, down from -$12.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$866000.0 in Q4 2022 to a low of -$45.4 million in Q2 2022.
• The 5-year median for Enterprise Value is -$14.2 million (2023), against an average of -$17.4 million.
• Across the five-year window, Enterprise Value surged 97.44% in 2022 and sank 989.15% in 2023, its largest moves.
• Insight Molecular Diagnostics' Enterprise Value stood at -$866000.0 in 2022, then tumbled by 989.15% to -$9.4 million in 2023, then gained by 8.44% to -$8.6 million in 2024, then sank by 42.57% to -$12.3 million in 2025, then sank by 134.97% to -$28.9 million in 2026.
• The last three Enterprise Value figures came in at -$28.9 million (Q1 2026), -$12.3 million (Q4 2025), and -$19.4 million (Q3 2025), per Business Quant data.